Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome
Brief Summary: The purpose of this study is to determine whether a daily supplement of 30 grams of walnut is effective in the treatment of metabolic syndrome (MetS).


Options:
A: Inclusion Criteria:

pubertal girls obese (BMI \> 30 kg/m) -

Exclusion Criteria:

Consumption of nuts Loss weight before the research chronic disease (hypertension)

-
B: Inclusion Criteria:

* Male and female age 25-75 years
* Non-smoker
* Overweight (BMI ≥ 25) with central adiposity as indicated by waist circumference (102 cm. in men / 88 cm. in women)
* Meet one risk factor of the metabolic syndrome.

  * blood pressure \> 130/85 or taking antihypertensive medication

    * fasting plasma glucose (FPG) \>100 mg/dL (6.1 mmol/L)
    * fasting serum triglycerides level (TG) \> 150 mg/dL (1.69 mmol/L)
    * fasting high-density lipoprotein (HDL) cholesterol \< 40 mg/dL (1.04 mmol/L)in men, and \< 50 mg/dL (1.29 mmol/L) in women.

Exclusion Criteria:

* Anticipated inability to complete or comply with study protocol
* Use of lipid-lowering or antihypertensive medications or aspirin unless stable on medication for at least 3 months and willing to refrain from taking medication for 12 hours prior to EF scanning
* Preexisting cardiovascular disease (including symptomatic coronary artery disease (CAD), myocardial infarction, angina pectoris, anginal equivalent, peripheral vascular disease, congestive heart failure, carotid stenosis)
* Severe hypertension (systolic blood pressure \>180mmHg or diastolic blood pressure \>105mmHg), even if well-controlled by medication.
* Diagnosed diabetes mellitus
* Regular use of multivitamins, Vitamin C, Vitamin E, fish oil, flax seed oil, omega-3 fatty acids, CoQ10, fiber supplements, garlic pills, arginine, red yeast rice, and any kind of antioxidant and unwillingness to discontinue supplementation for at least 4 weeks prior to study initiation and for study duration
* Allergic to walnuts or any other nuts
* Diagnosed eating disorder
* On any specific diet, weight control diet, vegan diet
* Any rheumatologic disease requiring regular use of NSAIDs or alternative medications
* Regular use of fiber supplements
* Regular use of vasoactive medication (including glucocorticoids, antineoplastic agents, psychoactive agents, or bronchodilators), and anticoagulant drugs (including Coumadin, plavix )
* Diagnosed sleep apnea
* Substance abuse (chronic alcoholism, other chemical dependency)
* Any unstable medical condition that would limit the ability of a subject to participate fully in the trial (e.g., cancer, AIDS, tuberculosis, psychotic disorder)
* Current or impending pregnancy
C: Inclusion Criteria:

* With metabolic syndrome. Metabolic syndrome was defined based upon the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian-Americans as presenting at least 3 of the following components: 1) waist circumference ≥ 90 cm for men or ≥ 80 cm for women; 2) triglycerides ≥1.7mmol/l; 3) HDL cholesterol \<1.03 for men or \<1.30 for women; 4) blood pressure ≥130/85 mmHg, or current use of antihypertentive medications; 5) fasting glucose ≥5.6mmol/l or previously diagnosed type 2 diabetes or on oral antidiabetic agents or insulin.
* Being able to comply with the specified feeding conditions
* Being able to eat walnuts
* Being between the ages of 35 and 60 years

Exclusion Criteria:

* Pregnancy or lactation
* Use of insulin
* Severe kidney disease
* Cardiovascular diseases, stroke, cancer and psychological disorders
* Walnut allergies or frequently eating walnuts or other nuts (\>90 grams/week)
* Drug or alcohol abuse.
D: Inclusion Criteria:

* Presence of a medical diagnosis of diabetes for at least 6 months
* HbA1c \< 9%
* Age greater than 18 years
* Resident of Loma Linda, California area

Exclusion Criteria:

* Allergy to peanuts
* Smokers
* History of irritable bowel disease or diverticulitis
* Statin therapy (unless stable statin dose for 3 months)

Answer: C